A possible strategy against head and neck cancer: In silico investigation of three-in-one inhibitors

Journal of Biomolecular Structure and Dynamics

Volumn 31, Issue 12, 2013, Pages 1358-1369

  Tsou, Yung An ^a,b   Chen, Kuan Chung ^a   Chang, Su Sen ^b   Wen, Yeong Ray ^b,c   Chen, Calvin Yu Chian ^a,b,d,e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

Epidermal growth factor receptor (EGFR); Head and neck cancer; Her2; Traditional Chinese medicine (TCM); Uroporphyrinogen decarboxylase (UROD)

Indexed keywords

(7 HYDROXYHEPTYL)OCTANEDIOATE; 9,12 DIHYDROXY 15 NONADECENOIC ACID; ALEURITIC ACID; ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINE; BINDING PROTEIN; COPROPORPHYRINOGEN III; DIHYDROFERULIC ACID; DOCOSANEDIOIC ACID; EICOSANEDIOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; NORBIXIN; PROTEIN UROD; SANLENG ACID; THREONINE; TIANSHIC ACID; UNCLASSIFIED DRUG; UROPORPHYRINOGEN DECARBOXYLASE;

ARTICLE; BINDING AFFINITY; CANCER RADIOTHERAPY; CATALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG STRUCTURE; HEAD AND NECK CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RADIATION RESPONSE; RECEPTOR AFFINITY;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DATABASES, FACTUAL; ENZYME INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; MEDICINE, CHINESE TRADITIONAL; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAIWAN; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 84887001993     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2012.736773     Document Type: Article

References (41)

1. Aertgeerts, K., Skene, R., Yano, J., Sang, B. C., Zou, H., Snell, G., ? Sogabe, S. (2011). Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. The Journal of Biological Chemistry, 286, 18756-18765.
2. Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983). CHARMM: A program for macromolecular energy minimization and dynamics calculations. Journal of Computational Chemistry, 4, 187-217.
3. Chang, S. S., Huang, H. J., & Chen, C. Y. C. (2011). Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine. PLoS Computational Biology, 7, e1002315.
4. Chang, K. W., Tsai, T. Y., Chen, K. C., Yang, S. C., Huang, H. J., Chang, T. T., ? Chen, C. Y. C. (2011). ISMART: An integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug design. Journal of Biomolecular Structure & Dynamics, 29, 243-250.
5. Chen, C. Y. C. (2008). A novel perspective on designing the inhibitor of HER2 receptor. Journal of the Chinese Institute of Chemical Engineers, 39, 291-299.
6. Chen, C. Y. C. (2010). Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors. Journal of the Taiwan Institute of Chemical Engineers, 41, 143-149.
7. Chen, C. Y. C. (2011). TCM database@Taiwan: The world?s largest traditional Chinese medicine database for drug screening in silico. PLoS ONE, 6, e15939.
8. Chen, K. Y., Chang, S. S., & Chen, C. Y. C. (2012). In silico identification of potent pancreatic triacylglycerol lipase inhibitors from traditional Chinese medicine. PLoS ONE, 7, e43932.
9. Chen, C. Y., & Chen, C. Y. C. (2010). Insights into designing the dual-targeted HER2/HSP90 inhibitors. Journal of Molecular Graphics & Modelling, 29, 21-31.
10. Chen, K. C., & Chen, C. Y. C. (2011). Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach. Soft Matter, 7, 4001-4008.
11. Chen, C. Y. C., Chen, G. W., & Chen, W. Y. C. (2008). Molecular simulation of HER2/neu degradation by inhibiting HSP90. Journal of the Chinese Chemical Society, 55, 297-302.
12. Chen, K. C., Sun, M. F., Yang, S. C., Chang, S. S., Chen, H. Y., Tsai, F. J., & Chen, C. Y. C. (2011). Investigation into potent inflammation inhibitors from traditional Chinese medicine. Chemical Biology & Drug Design, 78, 679-688.
13. de Andrade, D. A. P., & Machiels, J. P. (2012). Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Current Opinion in Oncology, 24, 211-217.
14. Fletcher, R. (1969). Optimization. New York, NY: Academic Press.
15. Herbst R. S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics, 59, 21-26. (Pubitemid 38610223)
16. Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4, 435-447.
17. Hoppmann, S., Qi, S. B., Miao, Z., Liu, H. G., Jiang, H., Cutler, C. S., ? Cheng, Z. (2012). Lu-177-DO3A-HSA-Z (EGFR:1907): Characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas. Journal of Biological Inorganic Chemistry, 17, 709-718.
18. Huang, H. J., Lee, K. J., Yu, H. W., Chen, C. Y., Hsu, C. H., Chen, H. Y., & Tsai, F. J. (2010). Structure-based and ligand-based drug design for HER 2 receptor. Journal of Biomolecular Structure & Dynamics, 28, 23-37.
19. Ito, E., Yip, K. W., & Liu, F. F. (2011). Uroporphyrinogen decarboxylase: Optimizing radiotherapy for head and neck cancer. Future Oncology, 7, 595-597.
20. Ito, E., Yue, S., Moriyama, E. H., Hui, A. B., Kim, I., Shi, W., ? Liu, F. F. (2011). Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Science Translational Medicine, 3, 67ra7.
21. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. Cancer Journal for Clinicians, 61, 69-90.
22. Kondo, N., Tsukuda, M., Sakakibara, A., Takahashi, H.,, H., Komatsu, M., ? Toth, G. (2012). Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines. International Journal of Oncology, 40, 1805-1812.
23. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46, 3-26. (Pubitemid 33653411)
24. Mannelli, G., & Gallo, O. (2012). Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treatment Reviews, 38, 515-539.
25. Nuyts, S., & Fairchild, A. (2012). Radiotherapy for head and neck cancer: An increasing dependence on innovative imaging. Onkologie, 35, 287-292.
26. Phillips, J. D., Whitby, F. G., Kushner, J. P., & Hill, C. P. (2003). Structural basis for tetrapyrrole coordination by uroporphyrinogen decarboxylase. The EMBO Journal, 22, 6225-6233. (Pubitemid 37522580)
27. Phillips, J. D., Whitby, F. G., Stadtmueller, B. M., Edwards, C. Q., Hill, C. P., & Kushner, J. P. (2007). Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Translational Research, 149, 85-91.
28. Ridge, J. A., Glisson, B. S., Lango, M. N., & Feigenberg, S. (2011). Head and neck tumors. In R. Pazdur, L. D. Wagman, K. A. Camphausen, & W. J. Hoskins (Eds.), Cancer management: A multidisciplinary approach. Retrieved from http://www.cancernetwork.com/cancer-management/head-and-neck/article/10165/ 1802498
29. Sun, M. F., Yang, S. C., Chang, K. W., Tsai, T. Y., Chen, H. Y., Tsai, F. J., ? Chen, C. Y. C. (2011). Screening from TCM Database@Taiwan and QSAR model for identifying HER2 inhibitors. Molecular Simulation, 37, 884-892.
30. Tirado-Rives, J., & Jorgensen, W. L. (2006). Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. Journal of Medicinal Chemistry, 49, 5880-5884. (Pubitemid 44484934)
31. Tou, W. I., & Chen, C. Y. (2012). In silico investigation of potential SRC kinase ligands from traditional Chinese medicine. PLoS ONE, 7, e33728.
32. Tsai, T. Y., Chang, K. W., & Chen, C. Y. C. (2011). IScreen: World's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan. Journal of Computer-Aided Molecular Design, 25, 525-531.
33. Tsai, K. N., Chen, G. W., & Chen, C. Y. C. (2012). A novel algorithm for identification of activated cryptic 5? splice sites. Journal of Biomolecular Structure & Dynamics, 29, 1089-1099.
34. Venkatachalam, C. M., Jiang, X., Oldfield, T., & Waldman, M. (2003). LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. Journal of Molecular Graphics and Modelling, 21, 289-307. (Pubitemid 35441326)
35. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., & Hong, W. K. (1993). Head and neck cancer. The New England Journal of Medicine, 328, 184-194.
36. Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995). LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Engineering, 8, 127-134.
37. Yang, S. C., Chang, S. S., & Chen, C. Y. C. (2011). Identifying HER2 inhibitors from natural products database. PLoS ONE, 6, e28793.
38. Yang, S. C., Chang, S. S., Chen, H. Y., & Chen, C. Y. C. (2011). Identification of potent EGFR inhibitors from TCM database@ Taiwan. PLoS Computational Biology, 7, e1002189.
39. Zhang, H., Yun, S., Batuwangala, T. D., Steward, M., Holmes, S. D., Pan, L.,? Shin, D. M. (2012). A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. International Journal of Cancer, 131, 956-969.
40. Zoete, V., Cuendet, M. A., Grosdidier, A., & Michielin, O. (2011). SwissParam: A fast force field generation tool for small organic molecules. Journal of Computational Chemistry, 32, 2359-2368.
41. Zygogianni, A., Kyrgias, G., Kouvaris, J., Pistevou-Gompaki, K., & Kouloulias, V. (2012). A new role of PET/CT for target delineation for radiotherapy treatment planning for head and neck carcinomas. Hellenic Journal of Nuclear Medicine, 15, 139-143.